APA

Schafer E. S., Rau R. E., Berg S., Liu X., Minard C. G., D'Adamo D., Scott R., Reyderman L., Martinez G., Devarajan S., Reid J. M., Fox E., Weigel B. J. & Blaney S. M. (20190510). A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). : Pediatric blood & cancer.

Chicago

Schafer Eric S, Rau Rachel E, Berg Stacey, Liu Xiaowei, Minard Charles G, D'Adamo David, Scott Rachael, Reyderman Larisa, Martinez Gresel, Devarajan Sandhya, Reid Joel M, Fox Elizabeth, Weigel Brenda J and Blaney Susan M. 20190510. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). : Pediatric blood & cancer.

Harvard

Schafer E. S., Rau R. E., Berg S., Liu X., Minard C. G., D'Adamo D., Scott R., Reyderman L., Martinez G., Devarajan S., Reid J. M., Fox E., Weigel B. J. and Blaney S. M. (20190510). A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). : Pediatric blood & cancer.

MLA

Schafer Eric S, Rau Rachel E, Berg Stacey, Liu Xiaowei, Minard Charles G, D'Adamo David, Scott Rachael, Reyderman Larisa, Martinez Gresel, Devarajan Sandhya, Reid Joel M, Fox Elizabeth, Weigel Brenda J and Blaney Susan M. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). : Pediatric blood & cancer. 20190510.